Systematic review maps pharmacogenomics-guided cardiovascular therapy in low- and middle-income countries
PLOS Global Public Health · Md. Farid Reza Mashfi, Sumiya Sharmin Mou, Monalisa Riya, Nasiba Binte Bahar, Tasnuha Islam, Fayek Rafi Ahmad, Fabliha Fatima, Md. Elias Al-Mamun · Published on Readzer
Summary
A systematic review of 24 studies (2020–2025) found that genotype-guided warfarin dosing nearly quintupled time in therapeutic INR range versus standard care, and decision models supported cost-effectiveness of genotype-guided antiplatelet therapy. However, African-ancestry individuals comprised less than 1% of global PGx participants, and evidence certainty ranged from very low to moderate, with barriers including high testing costs, workforce shortages, and low physician genetic knowledge.
This is a reviewed summary. Read the complete article at the original source.
Why it matters by industry
- Healthcare & Life Sciences
Directly relevant to cardiovascular medicine and pharmacogenomics, providing a synthesized evidence base on efficacy, cost-effectiveness, and equity gaps in LMICs, which informs clinical implementation and public health policy.